Financial Data and Key Metrics Changes - In Q4 2025, sales increased by 2% to $10.8 billion, with adjusted EBIT margin expanding by 100 basis points to 7.5% [8][12] - For the full year, sales were $42 billion, slightly down due to softer volumes in North America and Europe, while adjusted EBIT margin rose by 20 basis points to 5.6% [9][12] - Adjusted EPS for Q4 rose by 29% to $2.18, and for the full year, it increased by 6% to $5.73 [8][9] - Free cash flow for the full year reached $1.9 billion, an increase of $849 million [9][18] Business Line Data and Key Metrics Changes - Three of the four segments posted higher sales year-over-year, with seating seeing an 8% increase, while complete vehicles were down 10% [16] - Body exteriors and structures, and seating segments posted strong increases in adjusted EBIT margin year-over-year [16][17] - Power and vision margins were negatively impacted by discrete items, but operational improvements are expected to drive margin expansion in 2026 [17][61] Market Data and Key Metrics Changes - Global light vehicle production was down 1% overall in Q4, with North America and China declining, while Europe saw an increase [13] - Magna's sales growth is expected to be near flat to up 3.5% in 2026, driven by new program launches and foreign currency translation benefits [21][22] Company Strategy and Development Direction - The company is focused on operational excellence initiatives, which contributed to margin expansion and are expected to continue delivering benefits in 2026 [10][27] - A disciplined approach to capital spending is emphasized, with plans to repurchase approximately 22 million shares under the NCIB [7][24] - The company aims to maintain strong free cash flow and EPS growth while reducing leverage [7][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in executing their capital allocation strategy and driving EPS growth alongside strong free cash flow [7][28] - The outlook for 2026 includes expectations for adjusted EBIT margin expansion of 40-100 basis points and free cash flow of $1.6 billion to $1.8 billion [7][22] Other Important Information - The company achieved significant operational milestones in 2025, including securing 90% of its 2028 business and receiving 151 customer awards for quality and performance [9][10] - The company has been recognized as one of the world's most ethical companies and most admired companies [11] Q&A Session Summary Question: Guidance for outgrowth ex complete vehicles of 1%-4% - Management attributed the outgrowth to operational excellence activities and new programs with favorable economic terms [31][34] Question: Operational excellence and commercial recoveries - Management indicated that operational excellence is a continuing journey with visibility on margin improvements, while commercial recoveries are expected to be neutral year-over-year [36][39] Question: Seating segment outlook and cost actions - Management confirmed that no incumbent seating programs have been lost, and the seating segment remains core and profitable despite some program roll-offs [44][46] Question: Free cash flow sustainability - Management expects free cash flow in the range of $1.6 billion to $1.8 billion to be sustainable, supported by disciplined CapEx [49] Question: Ford recall and warranty hit - Management clarified that one recall matter has been resolved, while another is ongoing, impacting margins in the power and vision segment [52][59] Question: Growth in power and vision segment - Management highlighted that growth is driven by new launches and operational improvements, with expectations for margin expansion in 2026 [61][62]

Financial Data and Key Metrics Changes - Revenue for the fiscal quarter increased 105% year-over-year to $2.2 million, compared to $1.1 million for the same period last year [6][17] - Gross profit increased to $300,000 for the fiscal third quarter 2026, compared to a gross loss of $200,000 for the same period last year [18] - Net loss attributed to common stockholders was $7.3 million, or a loss of $0.85 per share, compared to a net loss of $13 million, or a loss of $2.96 per share in the previous year [20] Business Line Data and Key Metrics Changes - The core business, specifically the LungFit PH system, has seen significant adoption with over 45 hospitals now using the first-generation system [6][7] - Customer retention exceeds 90%, with more than half of customers under multi-year agreements [7] - The company is preparing for the anticipated FDA decision for the second-generation system, expected before the end of calendar 2026 [7] Market Data and Key Metrics Changes - The company has expanded its global distribution network for LungFit PH, now covering 40 countries [10] - Recent sales include the first sale to a VA Medical Center, establishing a foothold in the largest healthcare network in the U.S. [10] - The company has agreements with national group purchasing organizations, providing access to nearly 3,000 hospitals across the U.S. [9] Company Strategy and Development Direction - The company has made a strategic decision to sell its Neuronas subsidiary, which is expected to create long-term value for shareholders [5][15] - The focus remains on expanding the utilization of the first-generation system while preparing for the launch of the second-generation system [7][8] - The second-generation system is designed to offer reduced size and weight, simplified operation, and improved functionality, which is expected to expand the addressable market [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the trajectory of the business, citing strong team dedication and positive customer feedback [11] - The company is focused on disciplined execution and delivering advanced nitric oxide solutions to clinicians and patients globally [16] - Management is optimistic about the ongoing communication with the FDA regarding the second-generation system, indicating no major hurdles [40] Other Important Information - The company completed a $5 million financing in January 2026, providing resources to support commercial execution [16] - Cash, cash equivalents, and marketable securities totaled $17.8 million as of December 31, 2025, providing a cash runway into calendar year 2027 [21] Q&A Session Summary Question: Sales process and penetrating healthcare systems - The product is offered through the ECAT system, making it easier for customers to access without going through an RFP process [25][28] Question: Identifying facilities for system acquisition - The company is refining its commercial organization and using prospecting tools to identify and engage potential customers effectively [29][30] Question: Length of the sales cycle - The sales cycle remains around 6-9 months, with efforts to identify customers early in their contract processes [31][32] Question: Concerns about next-generation system affecting current sales - The focus is on the first-generation product while being aware of future conversations regarding the next-generation system [34] Question: FDA communications regarding the second-generation system - The company has had constant communication with the FDA and is confident in the timeline for approval [40] Question: International market wins and catalysts - Recent wins include setting up distributors with demo devices, leading to reorder of filters from hospitals [45] Question: Interest from XTL Biopharmaceuticals in Neuronas - The attractiveness of the Neuronas opportunity lies in the science and clear path to human studies [50][52] Question: COGS performance and future expectations - Long-term COGS is expected to be in the 60% range for Gen 1 and moving towards 70% for Gen 2 [55][56] Question: Impact of increased SG&A on revenues - The relationship between increased SG&A and revenue generation is being evaluated, with no definitive conclusions yet [60]

Ingersoll Rand (NYSE:IR) Q4 2025 Earnings call February 13, 2026 08:00 AM ET Company ParticipantsDavid Raso - Senior Managing Director and PartnerJeff Sprague - Founder and Managing PartnerMatthew Fort - VP of Investor RelationsNigel Coe - Managing Director and the Head of US Capital Goods Equity ResearchVicente Reynal - Chairman and CEOVik Kini - CFOConference Call ParticipantsAndrew Buscaglia - Senior Analyst for US Industrial TechnologyChris Snyder - Executive Director and Equity Research AnalystJoe O'De ...

February 13th, 2026 Greg Ebel President & CEO Pat Murray EVP & CFO Reconciliations of forward-looking non-GAAP and other financial measures to comparable GAAP measures are not available due to the challenges and impracticability of estimating certain items, particularly certain contingent liabilities and non-cash unrealized derivative fair value losses and gains which are subject to market variability. Because of those challenges, reconciliations of forward-looking non-GAAP and other financial measures are ...

YEAR END 2025 EARNINGS REPORT February 13, 2026 Safe Harbor Statement All per-share amounts in this presentation are reported on a diluted basis. The only common equity securities that are publicly traded are common shares of Eversource Energy. The earnings discussion includes financial measures that are not recognized under generally accepted accounting principles (non-GAAP) referencing earnings and EPS excluding losses associated with our previous offshore wind investments, a loss on the pending sale of t ...

Financial Data and Key Metrics Changes - Consolidated revenue for Q3 was CAD 1.25 billion, a 2% increase year-over-year [14] - Adjusted Segment Operating Income rose to CAD 195.8 million, up 3% from CAD 190 million in the same quarter last year [14] - Adjusted EPS increased to CAD 0.34, compared to CAD 0.29 a year ago [14] - Net finance expense decreased to CAD 54.1 million from CAD 56.6 million in the previous year [15] - Free cash flow was CAD 411.3 million, slightly above CAD 409.8 million recorded in the same quarter last year [17] - Capital expenditures totaled CAD 50.6 million, with expectations for full-year CapEx to be over 10% lower than last year [17] Business Line Data and Key Metrics Changes - In the civil segment, Q3 revenue decreased by 5% year-over-year to CAD 717.2 million, with adjusted operating income down 6% to CAD 141.8 million [18] - Defense segment revenue increased by 14% year-over-year to CAD 534.9 million, with adjusted operating income up 38% to CAD 54 million, achieving a margin of 10.1% [19] Market Data and Key Metrics Changes - The civil aviation market is expected to grow at 4%-5% annually over the long term, despite current softness [29] - Defense spending is projected to grow significantly, with Canada committing CAD 82 billion over the next five years [33] Company Strategy and Development Direction - The company is implementing a multi-pronged transformation plan focusing on portfolio sharpening, disciplined capital management, and operational excellence [4][5] - The transformation plan aims to increase earnings and cash flow while creating long-term sustainable value [5] - The company is rationalizing its civil training network to align capacity with current demand and improve utilization [30][39] Management's Comments on Operating Environment and Future Outlook - Management acknowledges near-term revenue impacts from transformation actions but believes these are necessary for long-term resilience and returns [6] - The defense segment is expected to see adjusted segment operating income growth of over 20% year-over-year, surpassing previous guidance [32] - The company anticipates the fourth quarter to be the strongest of the year in the civil segment, despite a mid-single-digit percentage decline in annual adjusted segment operating income [29] Other Important Information - The company has identified non-core assets representing approximately 8% of revenue for potential divestiture [36] - Recent leadership changes include the appointment of Ryan McLeod as Chief Financial Officer, expected to enhance operational finance and transformation execution [12] Q&A Session Summary Question: Long-term perspective on civil business returns - Management indicated that the civil business could generate solid mid-teen returns over the next few years, with a focus on improving utilization and profitability [50][53] Question: Conversations with civil customers regarding network rationalization - Initial conversations with civil customers have been positive, focusing on resizing the network to meet current demand [59][60] Question: Nature of identified non-core assets - Non-core assets are present in both civil and defense segments, and the company is focused on ensuring these businesses perform better under different ownership [67] Question: Outlook for civil aviation training demand - Management noted that while current demand is softer than expected, the long-term growth trajectory remains strong at 4%-5% [72][74] Question: Defense margins and contract performance - Defense margins improved due to a favorable contract mix and cost control measures, with expectations for continued margin expansion [78][80]

4Q2025 Supplemental Information FURNISHED AS OF FEBRUARY 12, 2026 - UNAUDITED FORWARD LOOKING STATEMENTS & RISK FACTORS This Supplemental Information report contains disclosures that are "forward-looking statements." Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as "may," "will," "expect," "believe," "anticipate," "target," "intend," "plan," "estimate," "project," "continue," "should," "could," "budge ...

Financial Data and Key Metrics Changes - In 2025, the company reported revenues of $1.9 billion, primarily driven by sales of its COVID vaccine Spikevax and mNEXSPIKE [5][11] - Operating expenses decreased by $2.2 billion, or 30%, compared to the previous year [5] - The net loss for the year was $2.8 billion, an improvement from a net loss of $3.6 billion in 2024 [14] - The company ended the year with $8.1 billion in cash and investments, down from $9.5 billion at the end of 2024 [14][15] Business Line Data and Key Metrics Changes - The company had three products on the market in 2025: Spikevax, mNEXSPIKE, and mRESVIA, with mNEXSPIKE quickly becoming the leading product in the U.S. [7] - For the fourth quarter, total revenue was $700 million, with $300 million from the U.S. and $400 million from international markets [11] - The U.S. revenue totaled $1.2 billion for the full year, while international revenue was $700 million [11] Market Data and Key Metrics Changes - In the U.S., despite a decline in overall COVID market demand, the company maintained strong market share in the retail channel, supported by the successful launch of mNEXSPIKE [12] - Internationally, operational performance and vaccination rates exceeded expectations, contributing to revenue growth [11] Company Strategy and Development Direction - The company aims for total revenue growth of up to 10% in 2026, primarily driven by international markets and local manufacturing agreements in the U.K. and Australia [15][16] - The company plans to launch mNEXSPIKE and its combination flu-COVID vaccine in Europe by the 2027 winter season, expanding its market share [20][21] - Strategic partnerships in Latin America and Asia Pacific are expected to drive growth, alongside the anticipated approval of its flu vaccine in multiple countries [21][27] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment over the FDA's refusal to file letter regarding the flu program, highlighting the challenges posed by regulatory uncertainty [6] - The company remains optimistic about its pipeline and expects continued clinical momentum, particularly in oncology and infectious disease programs [32][33] Other Important Information - The company has completed enrollment in several late-stage cancer studies and anticipates data readouts in 2026 [9][28] - A new Chief Development Officer, Dr. David Berman, will join the company, bringing extensive experience in clinical-stage immunotherapies [10] Q&A Session Summary Question: Implications of flu RTF on cash flow break-even guidance and INT program timing - Management noted that the flu filing is under review in Europe, Canada, and Australia, with the U.S. refile pending a Type A meeting with the FDA [36][37] - The INT program for adjuvant melanoma is event-driven, with data expected this year [42] Question: Thoughts on flu and COVID combination vaccine refile - The company is awaiting feedback from the FDA on what is needed to refile the mRNA-1010 program, with a comprehensive data set already submitted [45][47] - The phase III study for mRNA-1010 showed superior efficacy compared to standard vaccines [49][50] Question: European COVID vaccination market and flu vaccine strain selection - The company anticipates a larger market share in Europe, with mNEXSPIKE expected to be competitive [56][58] - Discussions on better strain matching for flu vaccines are ongoing, with strong support from international regulators [59][61]

Ingersoll Rand (NYSE:IR) Q4 2025 Earnings call February 13, 2026 08:00 AM ET Speaker13Hello, and welcome to the Ingersoll Rand fourth quarter 2025 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question, please press star one on your telephone keypad. I would now like to turn the conference over to Matthew Fort, Vice President, Investor Relations. You may begin.Speaker7Tha ...

Financial Data and Key Metrics Changes - In Q4 2025, sales increased by 2% to $10.8 billion, with adjusted EBIT margin expanding by 100 basis points to 7.5% [7][12] - For the full year, sales were $42 billion, slightly down due to softer volumes in North America and Europe, while adjusted EBIT margin rose by 20 basis points to 5.6% [8][9] - Adjusted EPS rose by 29% in Q4 to $2.18 and increased by 6% for the full year to $5.73 [7][8] - Free cash flow for the full year reached $1.9 billion, an increase of $849 million [8][18] Business Line Data and Key Metrics Changes - Three of the four segments posted higher sales year-over-year, with seating increasing by 8%, while complete vehicles saw a decline of 10% [16] - Adjusted EBIT margin for body exteriors and structures and seating improved year-over-year, with seating margins benefiting from a warranty pool reversal [16][17] - Power and vision margins were negatively impacted by discrete items, but operational improvements are expected to drive margin expansion in 2026 [17] Market Data and Key Metrics Changes - Global light vehicle production was down 1% overall in Q4, with North America and China declining, while Europe saw an increase [13] - Magna's sales growth is expected to be near flat to up 3.5% in 2026, driven by new program launches and foreign currency translation [21] Company Strategy and Development Direction - The company is focused on operational excellence initiatives, which contributed to margin expansion and are expected to continue delivering benefits in 2026 [10][26] - A disciplined approach to capital spending is emphasized, with plans to repurchase approximately 22 million shares in 2026 while maintaining financial flexibility [6][24] - The outlook for 2026 includes expected adjusted EBIT margin expansion of 40-100 basis points and strong free cash flow [22][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in executing their capital allocation strategy and driving EPS growth alongside strong free cash flow [6][26] - The company anticipates a relatively flat light vehicle production environment overall, with slight declines in North America and China offset by increases in Europe [20][21] - Management highlighted the importance of operational excellence and customer recoveries in achieving financial targets [31][38] Other Important Information - The company achieved significant milestones in 2025, including hitting annual bookings targets and securing 90% of its 2028 business [9] - Magna was recognized as one of the world's most ethical companies and most admired companies, reflecting strong corporate governance [11] Q&A Session Summary Question: Guidance for outgrowth excluding complete vehicles - Management attributed the outgrowth guidance of 1%-4% to operational excellence activities and new program launches [29][31] Question: Operational excellence and commercial recoveries - Management confirmed that operational excellence is a continuing journey, with expectations for ongoing margin improvements [35][36] Question: Seating segment outlook - Management reassured that seating remains a core business, with no loss of incumbent programs, and highlighted the impact of program roll-offs on margins [45][46] Question: Free cash flow sustainability - Management indicated that the guidance for free cash flow in 2026 is sustainable, targeting a conversion of 100% on net income [51][52] Question: Ford recall and warranty impacts - Management clarified that one recall matter was resolved, while another is ongoing, impacting margins in the power and vision segment [54][63] Question: Growth in power and vision segment - Management noted that growth in the power and vision segment is driven by new launches and operational improvements [64][66]